TapImmune’s lead candidate, TPIV200, a multiple-epitope anti-folate receptor alpha (FRα) immunotherapy, with an FDA orphan drug designation, has paired up with AstraZeneca’s checkpoint inhibitor Imfinzi in platinum-resistant ovarian cancer patients.
Tapimmune Inc. President & CEO, Peter Hoang, participates in an interview with The Wall Street Analyzer. Take a listen.
US-based immuno-oncology firm TapImmune has completed patient enrolment in a Phase II clinical trial of its vaccine candidate TPIV200 to treat triple-negative breast cancer (TNBC).
TapImmune has enrolled its final patient in a randomized, Phase 2 clinical study of an immunotherapy that targets breast cancer.
Peter Hoang loves being on the cutting-edge, and he believes Jacksonville-based TapImmune, Inc., which named him president and CEO Sept. 25, is there.
There are three trials that are really going to drive value for this company over the coming 24 months.
TapImmune Inc. has a new chief executive officer. Peter Hoang, the former head of business development and strategy at Bellicum Pharmaceuticals, will take over for CEO Glynn Wilson, who has been reappointed to the position of chairman of the board of directors.
Second Quarterly Call Earnings Call Transcript
TapImmune has amended the criteria for patient enrollment in a Phase 2 clinical trial testing its T-cell vaccine, TPIV 200, in women with ovarian cancer.
A Florida-based biotechnology company has received fast-track designation from the Food and Drug Administration to develop immunotherapy treatments for ovarian and breast cancers.